Dendritic Cells-Derived Exosomes in Human Sepsis

NCT ID: NCT02957279

Last Updated: 2016-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-11-30

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The amount of peripheral blood exosomes has been confirmed to change in the endotoxin-induced infection. The primary objectives of this study are to compare the changes of peripheral blood dendritic cell-derived exosomes in the patients with sepsis and the healthy controls.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, single-centered, clinical cohort study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

sepsis exosomes dendritic cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sepsis group

The patients were admitted to the Jinling Hospital, who met the diagnosis of sepsis(Sepsis 3.0).

Antibiotics

Intervention Type DRUG

In the sepsis group, antibiotics were used when needed.

Healthy control group

Healthy volunteers.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Antibiotics

In the sepsis group, antibiotics were used when needed.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients were selected with the diagnostic standard "Sepsis 3.0".
* Healthy volunteers do not have serious illness.

Exclusion Criteria

* Patients or volunteers do not agree to provide written informed consent and / or can not be legally authorized to provide informed consent.
* Patients give up treatments.
* Patients or volunteers withdrew from the study.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jinling Hospital, China

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jianan Ren

President of department of surgery, Jinling Hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jianan Ren, MD

Role: PRINCIPAL_INVESTIGATOR

Jinling Hospital, Medical School of Nanjing University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jinling Hospital, Medical School of Nanjing University

Nanjing, Jiangsu, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jianan Ren, MD

Role: CONTACT

Phone: 862580860108

Email: [email protected]

Yuan Li, MD

Role: CONTACT

Phone: 8615751866716

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jianan Ren, MD

Role: primary

Yuan Li, MD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20161103

Identifier Type: -

Identifier Source: org_study_id